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Background: This phase I study was performed to determine the
dose-limiting toxicity and maximum tolerated dose (MTD) of do-
cetaxel in combination with bortezomib in patients with advanced
non-small cell lung cancer (NSCLC) or other solid tumors.
Methods: Patients were enrolled in cohorts of three over six dose
levels. Each treatment cycle was 3 weeks long and consisted of one
docetaxel infusion (day 1) and four bortezomib injections (days 1, 4,
8, and 11). Dose escalation and MTD determination were based on
the occurrence of dose-limiting toxicities in cycle 1 only.
Results: A total of 36 patients were enrolled, 26 of whom had
NSCLC. All patients received at least one dose of study drug at one
of five dose levels. The MTD of the combined regimen was
determined to be 1.0/75 mg/m2 bortezomib/docetaxel. The combi-
nation was generally well tolerated. Toxicities were manageable,
and no additive toxicities were observed. The most common adverse
events were fatigue (67% of patients), nausea (50%), diarrhea
(39%), and neutropenia (39%). Two patients with NSCLC achieved
a partial response, and seven (19%) patients achieved stable disease
(including six patients with NSCLC).
Conclusion: The combination of bortezomib and docetaxel was
feasible and well tolerated in patients with advanced NSCLC or
other solid tumors. The recommended phase II dose is bortezomib
1.0 mg/m2 on days 1, 4, 8, and 11 plus docetaxel 75mg/m2 on day
1, cycled every 21 days. Therapeutic doses of docetaxel and bort-
ezomib are achievable for this combination.
Key Words: Bortezomib, Docetaxel, Non-small cell lung cancer,
Proteasome.
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In recent years, the inhibition of the 26S proteasome hasemerged as a rational anti-neoplastic strategy. The 26S
proteasome is a very large proteolytic complex involved in a
significant catabolic pathway, the ubiquitin–proteasome path-
way, for many intracellular regulatory proteins, including IB
kinase/nuclear factor-B (IB/NF-B), p53, and the cyclin-
dependent kinase inhibitors p21 and p27, which contribute to
the regulation of the cell cycle, apoptosis, and angiogene-
sis.1–3 It consists of a 19S cap on both ends, which recognizes
ubiquitin-tagged proteins that are marked for degradation,
and a 20S core, which contains three kinds of proteolytically
active sites: chymotrypsin-like, caspase-like, and trypsin-
like.2,4 Disrupting the ubiquitin–proteasome pathway can
affect tumor growth, proliferation, and apoptosis and is there-
fore an attractive target for anticancer therapy.1,5 The inhibi-
tion of proteasome function may, through multiple mecha-
nisms, lead to arrested growth of malignant cells, impaired
tumor angiogenesis, decreased metastasis, and sensitization
of cells to chemotherapeutic agents.
Bortezomib (VELCADE, Millennium Pharmaceuticals,
Cambridge, MA) is a proteasome inhibitor with proven clin-
ical activity in multiple myeloma6 that is presently being
evaluated for activity in solid tumors, including non-small
cell lung cancer (NSCLC).7,8 It is a boronic acid dipeptide
derivative and a selective and potent inhibitor of the 26S
proteasome.9,10 In the National Cancer Institute (NCI) cell
line screen, bortezomib demonstrated a unique pattern of
cytotoxic activity and growth inhibition against a broad range
of tumor types, with an average GI50 of 7 nM.9 Analysis
using the COMPARE algorithm11 showed that cytotoxicity
stemming from bortezomib was unique among all cancer
drugs in its molecular mechanism of action.
Preliminary in vitro studies have shown that bort-
ezomib alone can induce growth inhibition in A549, H520,
H460, H358, and H322 NSCLC tumor cell lines.12–16 We
have previously reported that bortezomib therapy stabilizes
p21 and p27 in NSCLC A549 cells.17 In Bold et al.’s study
with MIA-PaCa-2 cells, 18 bortezomib caused the accumula-
tion of p21 and p27 and a complete decrease in Bcl-2;
resistance to chemotherapy-induced apoptosis mediated by
Bcl-2 overexpression was bypassed. A common abnormality
defined in human tumors is the loss of p27 protein as a result
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of increased ubiquitin activity. Loss of p27 is associated with
a poor prognosis in many tumor types, including NSCLC.19,20
Conversely, overexpression of p27 triggers apoptosis in sev-
eral different human cancer cell lines.21 Meanwhile, abnor-
mal overexpression of Bcl-2 is found in approximately 20 to
25% of NSCLC and is associated with resistance to chemo-
therapy-induced apoptosis.22
When bortezomib is combined with standard chemo-
therapeutic agents, results have shown an enhanced antitumor
effect in NSCLC and other solid tumor cells.14,18,23,24 Bort-
ezomib may sensitize tumor cells to chemotherapy-induced
apoptosis through mechanisms of cell-cycle dysregula-
tion.16,24 Bortezomib plus docetaxel has been shown to have
significant additive cytotoxicity in SKOV3 human ovarian
carcinoma cells.25 This was confirmed in an in vivo study of
athymic nude mice inoculated with SKOV3 cells, in which a
significantly greater reduction in tumor growth was seen in
the group treated with combined bortezomib and docetaxel
compared with either monotherapy group.26 Our own studies
in NSCLC cell lines with bortezomib as a single agent or in
combination with docetaxel suggest a general model to ex-
plain the varied responses seen with the sequences of do-
cetaxel followed by bortezomib.17,27 We found that treatment
with docetaxel induces the accumulation and phosphorylation
of p27 and the phosphorylation of Bcl-2. The addition of
bortezomib to cells maintains the p27 induction and decreases
the levels of Bcl-2. These effects enhance docetaxel cytotox-
icity.
The aim of this phase I trial was to establish the
dose-limiting toxicity (DLT) and maximum tolerated dose
(MTD) of bortezomib and docetaxel combination therapy in
patients with locally advanced or metastatic NSCLC or other
solid tumors. In this dose-escalation study, we examined
bortezomib at dose levels based on previous studies in pa-
tients with advanced solid tumors,7,28 in combination with
docetaxel at escalating doses up to the standard dose of 75
mg/m2.29
PATIENTS AND METHODS
Patients
Institutional review boards at each of the study centers
approved the study, and all patients provided written in-
formed consent before any study-related procedures took
place. Patients with histologically confirmed locally ad-
vanced or metastatic NSCLC as well as other solid tumors,
who were treatment-naı¨ve or had previously received up to
two chemotherapy regimens, were enrolled subject to the
following main inclusion criteria: (1): age 8 years; (2)
measurable or evaluable disease; (3) Karnofsky Performance
Status (KPS) 60; (4) life expectancy 3 months; and (5)
adequate hematologic, renal, and hepatic end-organ function.
Patients were excluded if they had: (1) previously received
docetaxel, cisplatin (at a cumulative dose 350 mg/m2), or
radiation therapy to 25% of bone marrow; (2) grade 2 or
higher peripheral neuropathy; (3) electrocardiographic evi-
dence of acute ischemia or new conduction system abnormal-
ities; or (4) uncontrolled brain metastases or central nervous
system disease.
Study Design
This phase I, open-label, dose-escalation study was
conducted at four centers in the United States. Each treatment
cycle was 3 weeks in duration and consisted of one docetaxel
infusion (day 1) and four bortezomib injections (days 1, 4, 8,
and 11) followed by a 10-day rest period (days 12 to 21).
Cycle 2 was to commence on day 22 (cycle 2, day 1). A full
course of treatment was defined as eight treatment cycles
(eight docetaxel doses and 32 bortezomib doses); however,
patients who experienced symptomatic benefit from treatment
were permitted to receive further treatment after discussion
between the investigator and the sponsor.
On day 1 of each cycle, bortezomib was administered 1
hour after completion of the 1-hour docetaxel infusion, ac-
cording to the planned dose escalation (Table 1), in accor-
dance with the schedule considered to be optimal in preclin-
TABLE 1. Planned Study Drug Doses
Cohort
Number of patients
Dose (mg/m2)
Initial
enrollment
Additional enrollment,
if 1 of 3 initial patients has a DLT
Expanded enrollment,
if 0 of 3 or <1 of 6 has a DLTaBortezomib Docetaxel
1 1.0 60 3 3 10
2 65 3 3
3 70 3 3
4 75 3 3
5 1.3 75 3 3 3†
6 1.5 75 3 3
DLT, dose-limiting toxicity.
aThe low maximal tolerated dose (MTD) was the highest docetaxel dose in combination with bortezomib 1.0 mg/m2 at which 1 of 6 patients had a DLT. The high MTD was
the docetaxel dose in combination with bortezomib 1.3 mg/m2 or 1.5 mg/m2, at which 1 of 6 patients had a DLT. If an MTD was not established at either the low- or high-dose
bortezomib, then the additional enrollment in cohorts 4 and 6 was to be referred to as the low- and high-dose expanded cohorts (DEC), respectively. Additional patients enrolled at
the low-MTD/high-MTD or low-DEC/high-DEC were required to have a diagnosis of measurable NSCLC.
†A maximum of six patients were to be enrolled at the 1.3/75 mg/m2 and/or the 1.5/75 mg/m2 dose combinations of bortezomib and docetaxel, respectively. Expanded enrollment
at one of these dose combinations was to occur only if six patients had not already received doses at the cohort determined to be the high MTD or high-dose expanded cohorts.
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ical trials.30 Before each scheduled study drug dose, patients
were evaluated for possible toxicities that may have occurred
since the previous dose. A complete treatment cycle was
defined as one docetaxel and four bortezomib doses, as
specified above.
Dose escalation and determination of the MTD were
based on the occurrence of DLTs in cycle 1. Three patients
were to be enrolled at bortezomib 1.0 mg/m2 plus docetaxel
at a specified dose level. If no DLTs occurred in these first
three patients, enrollment commenced at the next dose level.
However, if one of the first three patients had a DLT, three
additional patients were to be enrolled at that dose level, and
only if none of these additional patients had a DLT could
enrollment commence at the next dose level. If at least two
patients in a cohort experienced a DLT, the previous dose
level was to be declared the MTD, and 10 additional patients
were to be enrolled at that dose level. The low MTD was the
highest docetaxel dose in combination with bortezomib 1.0
mg/m2 at which one or none of six patients had a DLT. The
high MTD was the highest docetaxel dose in combination
with bortezomib 1.3 or 1.5 mg/m2 at which one or none of six
patients had a DLT. If an MTD was not established at either
low- or high-dose bortezomib, additional enrollment in co-
horts 4 and 6 (Table 1) were to be referred to as the low- and
high-dose expanded cohorts, respectively. A maximum of six
patients were to be enrolled at the 1.3/75 mg/m2 and/or the
1.5/75 mg/m2 dose combinations of bortezomib and do-
cetaxel, respectively.
Toxicities were graded according to the NCI Common
Toxicity Criteria (NCI CTC, Version 2.0). The DLT was
based on observed adverse events after each study drug
administration in cycle 1 (days 1–21). The occurrence of any
of the following toxicities was considered a DLT if it was, in
the investigator’s opinion, related to the study drug: platelet
count 25,000 cells/mm3; febrile neutropenia (absolute neu-
trophil count [ANC] 1000 cells/mm3 with temperature
38.5°C); grade 4 neutropenia (ANC 500 cells/mm3 from
days 1 to 7 or ANC 200 cells/mm3 without fever of 7
days’ duration starting on or after day 8); grade 4 anemia
(hemoglobin 6.5 g/dL); grade 2 or greater peripheral neu-
ropathy; or any other grade 3 or greater toxicity, with the
exception of inadequately managed nausea, vomiting, and
diarrhea.
During each treatment cycle, KPS and body weight
were measured on days 1 and 11, and vital signs were
assessed on days 1, 4, 8, and 11. Laboratory samples were
collected for hematology, clinical chemistry, and urinalysis
on days 1, 4, 8, and 11 and for C-reactive protein (CRP) and
interleukin-6 (IL-6) on days 1 and 11. Blood samples for
pharmacodynamic assessment, performed using the 20S pro-
teasome inhibition assay,31 were obtained from all patients
before and 1 hour after bortezomib administration on days 1
and 11 of cycles 1 and 2 only.
Target and non-target lesions were measured by using
conventional methods, and the overall disease response was
assessed according to the Response Evaluation Criteria in
Solid Tumors (RECIST) guidelines.32
Safety, KPS, and efficacy evaluations were performed
during an end-of-therapy visit 10 days after administration of
the last bortezomib dose and during an end-of-study visit 3
weeks after the end-of-therapy visit.
Molecular Correlative Studies
The 20S proteasome inhibition assay provides a mea-
surement of percentage proteasome inhibition, the molecular
target of bortezomib. This assay was used to provide a more
relevant assessment than standard pharmacokinetic parame-
ters, which do not adequately guide dosing because bort-
ezomib rapidly exits the intravascular compartment.31 Blood
samples for assay were taken immediately before and 1 hour
after bortezomib dosing on days 1 and 11 of cycles 1 and 2
to show the effect of the bortezomib dosing schedule on
maximal percentage proteasome inhibition.
CRP and IL-6 are downstream indicators of proteasome
inhibition and were used to evaluate the efficacy of bort-
ezomib. Blood samples for the measurement of CRP and IL-6
were collected at the screening visit; on days 1 and 11 of
cycles 1, 2, 4, 6, and 8; and at the end-of-therapy and
end-of-study visits.
End Points
The primary end point was to establish the DLT and
MTD of bortezomib and docetaxel combination therapy.
Secondary end points included the overall disease response;
change from baseline in measurable tumors; time to con-
firmed disease response (complete response and partial re-
sponse [PR]); time to disease progression; duration of re-
sponse (time from start of response to start of progression);
change from baseline in KPS, CRP level, and IL-6 level; and
the pharmacodynamic analysis based on the 20S proteasome
inhibition assay.
Statistical Analysis
Statistical analyses were primarily descriptive because
the objective of the study was to determine the MTD after
escalating bortezomib and docetaxel doses. The MTD was
determined in the MTD-evaluable population, which was
defined as all patients who received bortezomib and docetaxel
and whose data were interpretable in the context of study
drug-specific toxicity (i.e., patients were to have had suffi-
cient safety assessments performed to determine whether a
DLT had occurred and were not to have received alternate
anti-neoplastic therapies through day 21 of cycle 1). Patients
in the expanded cohorts were excluded from the MTD-
evaluable population, as defined in the protocol. Patients who
were discontinued from the study for reasons other than DLT
before completing cycle 1 were not included in the analysis of
the MTD and were replaced. Overall response to therapy was
analyzed using a SAS algorithm based on the RECIST
guidelines. Changes in the sum of tumor measurements for
measurable lesions were calculated using radiographic mea-
surements provided by the investigators. All safety, efficacy,
and pharmacodynamic end point analyses were performed
using the intent-to-treat population, which was defined as all
patients who received at least one dose of study treatment.
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RESULTS
Patient Demographics
A total of 36 patients were enrolled in the study. All
patients received at least one dose of study drug at one of five
bortezomib/docetaxel dose levels: 1.0/60 (n 4), 1.0/65 (n
5), 1.0/70 (n  4), 1.0/75 (n  16), and 1.3/75 mg/m2 (n 
7) (Table 2). Most patients were male (22 of 36; 61%) and
white (27 of 36; 75%). Median age of the patients was 59.5
years (range, 42–79 years). Patient baseline demographics
and laboratory data were generally well balanced among dose
cohorts.
The most common primary diagnosis was lung cancer
(27 of 36 patients; 75%), and all but one of these 27 patients
had NSCLC. One (3%) patient each had a diagnosis of
pancreatic or prostate cancer; five (14%) patients had a
diagnosis of “other,” which included pleural mesothelioma or
gastric, small bowel, thyroid, or urinary bladder cancers; and
two (6%) patients had cancer of unknown primary site. A
total of 27 patients had received prior chemotherapy, whereas
13 patients had received prior radiation therapy.
DLT and MTD of Bortezomib in Combination
with Docetaxel
No patients in the first four dose cohorts experienced
DLTs during cycle 1. One patient at the 1.0/60 mg/m2 dose
level and two patients at the 1.0/65 mg/m2 dose level did not
complete cycle 1, receiving fewer than four bortezomib
doses. This was because of an unacceptable adverse event
(AE) (gastrointestinal hemorrhage) not related to study drug
in the patient at the lower dose level and to a bortezomib dose
being missed in error by two patients at the higher dose level.
All these patients were replaced and were excluded from the
MTD-evaluable population. One patient at the 1.0/70 mg/m2
dose level was excluded from the MTD-evaluable population
because of an incorrect dose calculation and was replaced. At
the 1.0/75 mg/m2 dose level, two patients did not complete
cycle 1, one because of a serious AE of bacteremia and one
because of patient request, and were replaced. One of these
replacement patients had a dose delayed in error and was
consequently replaced, resulting in an MTD-evaluable pop-
ulation of three patients.
Three patients were enrolled and treated at the 1.3/75
mg/m2 dose level. One of these three patients experienced a
DLT (grade 3 fatigue) at this dose level; therefore, three
further patients were enrolled. One of the original three
patients did not complete cycle 1, receiving fewer than four
bortezomib doses, and so was not included in the MTD-
evaluable population. This patient was not replaced because
three additional patients had already been enrolled at this
dose level. However, one of the three further patients to be
enrolled requested to be withdrawn from the study and so did
not complete cycle 1. A replacement patient was enrolled and
later experienced a DLT (grade 3 fatigue). Because two of
five MTD-evaluable patients experienced DLTs at this dose
level, the MTD for this study was declared to be 1.0/75
mg/m2 bortezomib and docetaxel, respectively, and the
1.0/75 mg/m2 bortezomib/docetaxel cohort was expanded
with 10 additional patients (Table 3).
KPS, CRP, and IL-6
At baseline, overall mean KPS values were 77.50,
84.00, 87.50, 81.33, and 81.67 in patients enrolled at the five
dose levels (lowest to highest, respectively). An overall mean
change from baseline in KPS of between 0 and 10 was
TABLE 2. Demographic and Baseline Characteristics
Bortezomib/docetaxel dose cohorts (mg/m2)
1.0/60 1.0/65 1.0/70 1.0/75 1.3/75 Total
n 4 5 4 16 7 36
Age, years
Mean (SD) 62.5 (7.94) 65.6 (7.50) 52.0 (5.35) 58.4 (10.34) 59.1 (11.70) 59.3 (9.84)
Median 60.0 62.0 51.5 59.0 61.0 59.5
Range 56–74 59–76 46–59 42–74 45–79 42–79
Gender, n (%)
Male 2 (50) 3 (60) 1 (25) 12 (75) 4 (57) 22 (61)
Female 2 (50) 2 (40) 3 (75) 4 (25) 3 (43) 14 (39)
Race, n (%)
White 4 (100) 4 (80) 2 (50) 10 (63) 7 (100) 27 (75)
Asian 0 0 1 (25) 4 (25) 0 5 (14)
Black 0 1 (20) 1 (25) 0 0 2 (6)
Hispanic 0 0 0 2 (13) 0 2 (6)
KPS, n (%)
70 1 (25) 1 (20) 0 4 (27) 3 (50) 9 (26)
80 3 (75) 2 (40) 1 (25) 5 (33) 0 11 (32)
90–100 0 2 (40) 3 (75) 6 (40) 3 (50) 14 (41)
Missing 0 0 0 1 1 2
KPS, Karnofsky Performance Status.
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observed for patients assessed at each time point up to cycle
8, the last cycle analyzed; these changes were generally
increases in KPS. At the end-of-therapy and end-of-study
visits, small mean decreases in KPS from baseline were
observed overall and at most dose levels. Overall median
baseline CRP level was 11.9 mg/L (range, 1.4–103.0 mg/L).
Generalized increases from baseline were observed in CRP
levels; however, there was no apparent trend among levels.
The overall median baseline IL-6 level was 5.0 pg/mL (range,
2.0–59.9 pg/mL). There was little or no change from baseline
in median IL-6 levels, and no apparent trend was observed
among dose levels.
Inhibition of 20S Proteasome Activity
Maximal inhibition of 20S proteasome activity was
observed 1 hour after dosing in all dosing cohorts in cycle 1
and cycle 2. There was a pattern of 20S proteasome activity
inhibition 1 hour after bortezomib administration, with a
return to baseline activity before the next scheduled dose
(Figure 1). Although the mean maximal percent inhibition
was similar between both bortezomib dose levels (1.0 and 1.3
mg/m2)—approximately 60% 1 hour after dosing on day 1,
cycle 1, and 69 to 82% 1 hour after dosing on day 11, cycle
1—there was a suggestion of increased inhibition with in-
creased dose. No apparent differences were observed with
increasing docetaxel dose levels (60–75 mg/m2). Most pa-
tients had 50% proteasome inhibition relative to baseline
before the next scheduled dose.
Safety
A total of 36 patients received at least one dose of the
study drug at one of five bortezomib/docetaxel dose levels.
Thirty-two (89%) patients completed at least one cycle of
treatment. An average of 4.4 (range, 0–33) and 3.3 (range,
0–11) treatment cycles were completed at the dose levels of
1.0 mg/m2 and 1.3 mg/m2 bortezomib, respectively. The
mean total dose of bortezomib administered during all treat-
ment cycles was 34.5 mg (range, 2.24–307.6 mg) during the
median treatment duration of 37.5 days (range, 1–718 days),
and the mean total dose of docetaxel administered during all
treatment cycles was 602.7 mg (range, 85.0–5508.7 mg)
during the median treatment duration of 37.5 days (range,
1–718 days).
As would be expected with this patient population, all
36 treated patients experienced at least one treatment-emer-
gent AE: 24 (67%) had fatigue, 18 (50%) experienced nausea,
14 (39%) had diarrhea not otherwise specified (NOS), and 14
(39%) had neutropenia. Other AEs occurring in 20% or more
of patients were: alopecia, myalgia, and peripheral neuropa-
thy NOS (10 patients each, 28%); anemia NOS, arthralgia,
and insomnia (nine patients each, 25%); and lower limb
edema and pyrexia (eight patients each, 22%). These AEs
were mostly of grade 1 or 2 intensity. All patients also
experienced at least one AE considered by the investigator to
be at least possibly related to bortezomib and/or docetaxel.
The most commonly reported treatment-related AEs were
fatigue (20 patients, 56%), neutropenia (14 patients, 39%),
and nausea (13 patients, 36%). Peripheral neuropathy (eight
patients, 22%), paraesthesia (four patients, 11%), dizziness
excluding vertigo (three patients, 8%), and headache NOS
(three patients, 8%), all of grade 1 or 2 intensity, were the
most commonly reported treatment-related AEs of the ner-
vous system.
Approximately two thirds of patients (22, 61%) expe-
rienced at least one AE of grade 3 or 4 intensity, 17 patients
(59%) who received bortezomib 1.0 mg/m2, and five patients
(71%) who received bortezomib 1.3 mg/m2 (Table 4). These
AEs were considered to be at least possibly related to bort-
ezomib and/or docetaxel in 17 patients (47%): 12 (41%) who
received bortezomib 1.0 mg/m2 and five (71%) who received
TABLE 3. Patient Disposition
Bortezomib/docetaxel doses (mg/m2)
1.0/60 1.0/65 1.0/70 1.0/75 1.3/75 Total
Enrolled n % 4 5 4 16 7 36
ITT populationa 4 (100) 5 (100) 4 (100) 16 (100) 7 (100) 36 (100)
MTD populationb 3 (75) 3 (60) 3 (75) 3 (19) 5 (71) 17 (47)
Completed the studyc 0 1 (20) 1 (25) 2 (13) 1 (14) 5 (14)
Terminated from the study early 4 (100) 4 (80) 3 (75) 14 (88) 6 (86) 31 (86)
Primary reason for early termination
Progressive disease 1 (25) 1 (20) 3 (75) 10 (63) 3 (43) 18 (50)
Patient request 0 2 (40) 0 2 (13) 1 (14) 5 (14)
Investigator judgmentd 1 (25) 1 (20) 0 1 (6) 1 (14) 4 (11)
Unacceptable AE 1 (25) 0 0 1 (6) 1 (14) 3 (8)
Noncompliance 1 (25) 0 0 0 0 1 (3)
ITT, intent to treat; MTD, maximal tolerated dose; AE, adverse event. Values are presented as n (%).
aPatients who received at least one dose of bortezomib or docetaxel.
bPatients who received bortezomib and docetaxel and completed cycle 1, and whose data were interpretable in the context of study drug-specific toxicity. Patients in the expansion
of cohort 4 were not included.
cPatients who completed eight treatment cycles were considered to have completed the study.
dThe investigator considered changes in the patient’s condition unacceptable for further treatment.
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bortezomib 1.3 mg/m2. The most commonly reported treat-
ment-related grade 3 or 4 toxicity was neutropenia (13 pa-
tients, 36%), which was reported for 10 patients (34%) who
received bortezomib 1.0 mg/m2 and three patients (43%) who
received bortezomib 1.3 mg/m2. Fatigue was the only other
study drug-related grade 3 or 4 toxicity reported for more
than 10% of patients; it was reported in four patients (11%)
overall: one patient (3%) who received bortezomib 1.0 mg/m2
and three patients (43%) who received bortezomib 1.3 mg/
m2. Eleven patients (31%) experienced at least one AE of
grade 4 intensity. Grade 4 neutropenia (nine patients, 25%)
and hyponatremia (one patient, 3%) were generally consid-
ered by the investigator to be at least possibly related to
bortezomib and/or docetaxel, whereas all other grade 4 events
were considered unlikely or not related to bortezomib and/or
docetaxel.
No patients needed to discontinue the study drugs
because of a treatment-related AE. Six patients (17%) and
FIGURE 1. Percent inhibition of
20S proteasome activity relative to
baseline (cycle 1, day 1 pre-dose).
TABLE 4. Most Commonly Reported (5%) Treatment-Emergent Adverse Effects of Grade 3 or 4 Intensitya
Cohort: Study drug dose of bortezomib/docetaxel (mg/m2)
MedDRA preferred term 1: 1.0/60 2: 1.0/65 3: 1.0/70 4: 1.0/75 Subtotal for cohorts 1–4 5: 1.3/75 Total
(n  4) (n  5) (n  4) (n  16) (n  29) (n  7) (n  36)
Patients with at least one
treatment-emergent AE
of grade 3 or 4 intensity
2 (50) 3 (60) 1 (25) 11 (69) 17 (59) 5 (71) 22 (61)
Neutropenia 1 (25) 2 (40) 1 (25) 6 (38) 10 (34) 3 (43) 13 (36)
Fatigue 0 0 0 2 (13) 2 (7) 3 (43) 5 (14)
Hyponatremia 0 0 0 2 (13) 2 (7) 1 (14) 3 (8)
Anxiety NEC 0 1 (20) 0 1 (6) 2 (7) 0 2 (6)
Dehydration 0 0 0 2 (13) 2 (7) 0 2 (6)
Device blockage 0 1 (20) 0 1 (6) 2 (7) 0 2 (6)
Disease progression NOS 0 0 1 (25) 0 1 (3) 1 (14) 2 (6)
Dyspnea exacerbated 0 1 (20) 0 1 (6) 2 (7) 0 2 (6)
Mental status changes 0 1 (20) 0 0 1 (3) 1 (14) 2 (6)
Values are expressed as n (%). MedDRA, Medical Dictionary for Regulatory Activities; NEC, not elsewhere classified; NOS, not otherwise specified; AE, adverse event.
aA patient was counted only once within a preferred term.
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one patient (3%) required dose reductions after cycles 2 and
4, respectively. Most patients (18; 50%) who were terminated
from the study early did so because of progressive disease,
and three patients (8%) were terminated because of a non–
study drug-related unacceptable AE (Table 3). These were
grade 4 gastrointestinal hemorrhage, grade 3 bacteremia, and
grade 4 disease progression NOS (generalized muscle atro-
phy likely related to hypothyroidism in a patient with med-
ullary carcinoma of the thyroid), in patients in the 1.0/60,
1.0/75, and 1.3/75 mg/m2 dose levels, respectively. The
patient withdrawn from the study for noncompliance had a
2-week non–safety-related delay between the last dose of
cycle 4 and the first dose of cycle 5. Two patient deaths
occurred during the study, one from an AE (gastrointestinal
hemorrhage) that began 12 days after the last study drug dose
and was not considered to be related to the study drugs, and
one from clinical deterioration 17 days after the last dose of
study drug; that patient was considered to have developed
progressive disease 14 days after the last dose of study drug
and had been withdrawn from the study before death.
Tumor Measurement and Assessment of
Disease Response
Of 36 patients, two achieved a PR as best overall
response, both occurring at the MTD (1.0/75 mg/m2 bort-
ezomib/docetaxel). Seven patients (19%) achieved stable dis-
ease, including three at 1.0/60 mg/m2 bortezomib/docetaxel,
one at 1.0/70 mg/m2 bortezomib/docetaxel, and three at
1.0/75 mg/m2 bortezomib/docetaxel dose levels (Table 5).
The two patients who achieved a PR had a diagnosis of stage
IV metastatic NSCLC, one classified as large cell carcinoma
and one as carcinoma. The former had received gemcitabine
plus carboplatin therapy, followed 3 months later by gefitinib,
after which he progressed. The latter patient had previously
received carboplatin plus paclitaxel, achieving a response of
stable disease. Of the nine patients showing response or
stable disease, eight (89%) had a primary diagnosis of
NSCLC.
The median percent change in tumor lesion size from
baseline through to cycle 8 was similar at each assessment,
and no difference was apparent with increasing dose. The
times to disease response for the two patients with a con-
firmed PR were 75 and 122 days, and the respective durations
of response were 68 and 84 days. The median time to disease
progression for all patients was 77 days.
DISCUSSION
This dose-escalation study of bortezomib and docetaxel
represents the initial clinical experiment using this combina-
tion to treat patients with locally advanced or metastatic
NSCLC and other solid tumors. We determined the MTD of
the combined regimen to be 1.0/75 mg/m2 bortezomib/do-
cetaxel. The study drugs were administered over a 3-week
treatment cycle consisting of one docetaxel infusion on day 1
and four bortezomib injections on days 1, 4, 8, and 11,
followed by a 10-day rest period (days 11–21).
The combination of bortezomib and docetaxel at the
MTD was generally well tolerated: no additive toxicities were
observed, and the reported toxicities were manageable in
most patients in this clinical study. No patient discontinued a
study drug because of a treatment-related AE. The overall
AEs were not unexpected in this population of patients with
locally advanced or metastatic NSCLC or among patients
receiving treatment with bortezomib and docetaxel. The char-
acteristics of the study population were consistent with those
seen in other phase I studies of NSCLC, with one half of
patients having relapsed or refractory cancer that had been
pretreated with multiple lines of prior chemotherapy.
The mean degree of inhibition of 20S proteasome
activity 1-hour after dosing observed in this study was com-
parable with that seen at similar doses in phase I studies of
bortezomib monotherapy.7,28,33–35 In addition, the suggestion
of increased inhibition with increased dose in this study is
supported by results from other studies indicating dose-
dependent inhibition.7,28,33–35 No association between inhibi-
tion of 20S proteasome activity and clinical response or
toxicity was observed in this study. Results from other clin-
ical studies indicate that the degree of 20S proteasome inhi-
bition observed in this study is sufficient to produce clinical
effects. Clinically relevant efficacy was observed at 65 to
80% inhibition in a phase I study in advanced solid tumors7
TABLE 5. Summary of Best Response to Treatment, Overall and by Dose Level (ITT Population)
Cohort: Study drug doses, bortezomib/docetaxel (mg/m2)
1: 1.0/60
(n  4)
2: 1.0/65
(n  5)
3: 1.0/70
(n  4)
4: 1.0/75
(n  16)
5: 1.3/75
(n  7)
Total
(n  36)a
Best response during study
per RECIST criteriab
PR 0 0 0 2 (13) 0 2 (6)
Stable disease 3 (75) 0 1 (25) 3 (19) 0 7 (19)
Progressive disease 0 2 (40) 3 (75) 7 (44) 3 (43) 15 (42)
ITT, intent to treat; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors.
aThe remaining 12 (33%) of the total of 36 patients were not assessable for disease response either because they had withdrawn from the study before the first disease assessment
or because they had insufficient data.
bOverall best response to therapy (including confirmed and unconfirmed responses) was computed by the sponsor based on the RECIST guidelines and includes data from day
1 of cycle 1 to the end-of-study visit. Patient 004-008 (1.3/75 mg/m2 dose level) had a PR according to the RECIST guidelines; however, this patient had clinical deterioration on
the same day and was withdrawn from the study and is therefore considered to have progressive disease.
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and at dose levels producing 60% inhibition in a phase I
study in refractory hematologic malignancies.35 Degree of
20S proteasome inhibition up to 65% was a significant
predictive factor for toxicity in the phase I study by Papan-
dreou et al.;7 however, most AEs were seen at 65 to 75% 20S
proteasome inhibition, and their severity did not correlate
with degree of inhibition. Nevertheless, the availability of a
20S proteasome assay31 has enabled the use of this parameter
as a guide in dose escalation studies.7,10,33 In animals, toxic-
ities become significantly more pronounced above 80% 20S
proteasome inhibition36; the dose estimated to produce this
degree of inhibition in humans, the maximal safe dose, has
been calculated as 1.96 mg/m2.36
To date, a number of phase II and phase III clinical
trials have shown that bortezomib alone and in combination
is well tolerated and active in multiple myeloma and non-
Hodgkin’s lymphoma,6,37–40 and activity has been seen in
prostate cancer and lung cancers in phase I trials.7,41–43 By
inhibiting protein degradation by the proteasome, bortezomib
targets multiple pathways significant to tumor progression
and can help to overcome multiple cellular drug resistance
associated with chemotherapeutic monotherapy.44 In
NSCLC, bortezomib monotherapy28,45 or bortezomib com-
bined with standard chemotherapy agents41–43,46 has shown
encouraging results.
The combination of bortezomib with docetaxel has
been evaluated in several other studies, and the MTD seems
to be highly dependent on the treatment schedule. In a phase
I study of patients with breast cancer, the bortezomib/do-
cetaxel combination was well tolerated, and all toxicities
were manageable. DLTs were not observed in patients with
breast cancer treated with 1.3/75 mg/m2 bortezomib/do-
cetaxel administered on the same schedule used in this
study.47 When docetaxel was given weekly for 2 weeks and
bortezomib twice weekly for 2 weeks of a 21-day cycle in
patients with refractory solid tumors, the MTD was only 25
mg/m2 and 0.8 mg/m2, respectively.43 However, in a phase
I/II study in patients with hormone-refractory prostate cancer,
the MTD was not reached, and docetaxel 40 mg/m2 on days
1 and 8 combined with bortezomib 1.6 mg/m2 on days 2 and
9 of a 21-day cycle was well tolerated.48
A number of practical issues should be considered
when integrating bortezomib chemosensitization into lung
cancer chemotherapy regimens. The optimal dosing schedule
needs to address the potential for DLTs (e.g., fatigue), the
optimal sequencing with various chemotherapeutic regimens,
and the duration of bortezomib treatment, including the
potential for cumulative toxicity with long-term administra-
tion.30 Comparative phase II studies are required to determine
the efficacy and toxicity advantages and disadvantages of
different bortezomib/docetaxel treatment schedules. The
schedule used in the present study delivers a higher dose
intensity of bortezomib and a similar dose intensity of do-
cetaxel over the 3-week cycle, in comparison with the weekly
schedule.48 Various administration schedules of bortezomib
monotherapy in phase I trials have produced comparable dose
intensities.7,28,33-35,49 However, a weekly schedule seems to
enable a greater dose per administration, and intermittent
dosing may better separate acute and cumulative bortezomib-
related toxicities.33 Meanwhile, a recent study has shown that
weekly docetaxel 40 mg/m2 results in a lower incidence of
grade 3 or 4 neutropenia compared with docetaxel 75 mg/m2
every 3 weeks. However, efficacy seemed to be slightly
lower.29
Determining antitumor activity was not the main goal
of the study. However, results from disease response assess-
ments show the combination of bortezomib and docetaxel to
be active in solid tumors, with a PR achieved in two patients
(both with NSCLC). Although preliminary, these results
suggest that bortezomib in combination with docetaxel is
active in the treatment of NSCLC. Indeed, this early prospec-
tive study is part of a larger program to evaluate the safety
and efficacy of bortezomib in NSCLC, as both monotherapy
and in combined regimens. Our group is conducting a NCI-
sponsored randomized phase II trial of two different sched-
ules of bortezomib plus docetaxel (concurrent versus sequen-
tial) as second-line treatment for patients with advanced
NSCLC.
In conclusion, toxicities were manageable when do-
cetaxel and bortezomib were administered in combination,
and the confirmed MTD indicates that the standard docetaxel
regimen should not need to be altered when administered
along with a clinically active dose of bortezomib for future
clinical efficacy studies.
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